Drug intelligence / Profile preview

Moisview

Development stage: Unknown
Lead developer: Huons
Modality: Small Molecules
Administration: Ophthalmic

Overview

Moisview is an ophthalmic solution indicated for the treatment of Dry Eye Syndrome. It is understood to be a trehalose 3% eye drop. Trehalose, a naturally occurring disaccharide, functions as an osmoprotectant, antioxidant, and cell stabilizer. It helps protect ocular surface cells from dehydration and oxidative stress, maintains tear film stability, reduces tear-film osmolarity, and supports the survival of corneal epithelial cells. Moisview is being evaluated in Phase III clinical trials for its efficacy and safety in patients with Dry Eye Syndrome.

Brand names: Moisview
Other names: Moisview Eye Drops

Beyond the preview

Go deeper on Moisview.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Moisview.

Explore the full profile